Oppenheimer Downgrades Celldex Therapeutics (CLDX) to Perform
Tweet Send to a Friend
Oppenheimer downgraded Celldex Therapeutics (NASDAQ: CLDX) from Outperform to Perform after the DSMB recommends discontinuation of Rindo.Analyst Christopher Marai commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE